JCR Pharmaceuticals Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JCRRF research report →
Price Chart
About the company
JCR Pharmaceuticals Co. , Ltd. , a specialized pharmaceutical company headquartered in Ashiya, Japan, and established in 1975, operates across the entire lifecycle of pharmaceutical products, regenerative medicines, and active drug substances.
- CEO
- Toru Ashida
- IPO
- 2021
- Employees
- 985
- HQ
- Ashiya, HY, JP
Get TickerSpark's AI analysis on JCRRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $455.12M
- P/E
- 78.42
- Fwd P/E
- 1.17
- PEG
- 1.21
- P/S
- 1.55
- P/B
- 1.49
- EV/EBITDA
- 23.99
- Div Yield
- 3.80%
- Gross Margin
- 75.60%
- Op Margin
- -2.48%
- Net Margin
- 1.97%
- ROE
- 1.77%
- ROIC
- -0.47%
Latest fiscal year · YoY change
- Revenue
- $40.57B+22.7%
- Gross Profit
- $30.25B+39.2%
- Op Income
- $433.71M
- Net Income
- $2.19B+146.1%
- EPS
- $17.58+145.7%
- OCF Growth
- +97.5%
- FCF Growth
- +24.3%
- 52W High
- $4.75
- 52W Low
- $3.14
- 50D MA
- $3.36
- 200D MA
- $3.83
- Beta
- 0.56
- RSI (14)
- 100
- Avg Volume
- 15
No earnings-call transcripts are available for JCRRF yet.
- Free Float
- 56.9%
- Shares Outstanding
- 122.02M
- Float Shares
- 69.44M
Our JCRRF coverage
Recent articles, reports, and earnings notes.
No research on JCRRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JCRRF report →Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America
businesswire.com · Oct 2
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
businesswire.com · Sep 28
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
businesswire.com · Sep 11
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
businesswire.com · Jul 21
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
businesswire.com · Jun 17
JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
businesswire.com · Jun 8
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
businesswire.com · May 28
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
businesswire.com · May 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.